Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia

NCT03774459 is registered in ClinicalTrials.gov with Anavex Life Sciences Corp. as lead sponsor.

NCT NCT03774459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03774459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia
Lead sponsor
Anavex Life Sciences Corp.
Phase
Phase 2
Overall status
Completed
Start date
July 9, 2018
Completion date
September 30, 2020
Enrollment
132 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

parkinsons disease with dementia